Medivir AB (OSTO:MVIR) Loans Receivable : kr0.00 Mil (As of Mar. 2025)

View and export this data going back to 1996. Start your Free Trial

What is Medivir AB Loans Receivable?

Medivir AB's Loans Receivable for the quarter that ended in Mar. 2025 was kr0.00 Mil.

Medivir AB Loans Receivable Historical Data

The historical data trend for Medivir AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Loans Receivable Chart

Medivir AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Loans Receivable

Get a 7-Day Free Trial

Medivir AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Medivir AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Medivir AB Loans Receivable Related Terms

Thank you for viewing the detailed overview of Medivir AB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OSTO:MVIR) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

0GP7:UK MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions.

Medivir AB Headlines

No Headlines